New Partnerships Added to World Federation of Hemophilia Twinning Program

Collegeville, Pennsylvania (ots/PRNewswire) -

- Wyeth and Advocacy Community Mark Continued Commitment to
Patient Care on World Hemophilia Day

In honor of the twentieth Anniversary of World Hemophilia Day,
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), together with
the World Federation of Hemophilia (WFH), announce the addition of
five new partnerships to the WFH Twinning Program. Begun in 1994, the
Twinning Program aims to increase the level of diagnosis and care for
people with hemophilia by pairing emerging treatment centers and
patient organizations with more established centers and organizations
around the world. Wyeth has been the sole corporate sponsor of the
program since 2001, which now includes a total of 31 partnerships
worldwide.

"Wyeth recognizes that effective collaboration between advocacy
organizations and industry can help people with chronic illnesses
such as hemophilia," says Angela Rossetti, Assistant Vice President,
and Global Business Manager for Wyeth Hemophilia. "Our continued
support of the Twinning Program -- now in its 16th year -- and other
advocacy initiatives is part of a global collaborative effort
designed to help patients with hemophilia and their families receive
access to better care."

The new Twinning partnerships include the following Hemophilia
Treatment Center Twins: Addis Ababa (Ethiopia) and Chapel Hill (North
Carolina, USA); Dakar (Senegal) and Paris (France); Quito (Ecuador)
and Caracas (Venezuela); Manipal (India) and Albuquerque, (New
Mexico, USA); Skopje (Macedonia) and Bonn (Germany). For more
information on the Twinning Program and to view a video of the Lima
(Peru) and Fort Worth (Texas, USA) Twin in action, visit www.wfh.org.

"World Hemophilia Day is an opportunity for all of us in the
bleeding disorders community to celebrate our achievements and raise
awareness," said Mark Skinner, WFH president. "The theme of this
year's World Hemophilia Day, 'Together, we care' embodies our spirit
of collaboration to work together to improve care for people with
bleeding disorders. We are grateful to Wyeth for its support of our
programs, especially the Twinning Program, which play a key role in
achieving our vision of Treatment for All."

THE HEMOPHILIA COMMUNITY AND WYETH: A HISTORY OF PARTNERSHIP

Support of Children's Camping Initiatives

For years, Wyeth has recognized the importance of the summer camp
experience to children in the bleeding disorders community. Since
1998, Wyeth has been a major sponsor of Barretstown in Ireland -- an
innovative recreational facility -- where children with serious
illnesses, including children with hemophilia, can participate in a
range of fun activities that also are designed to promote
self-confidence, independence, trust and coping skills. In addition
to its ongoing support, Wyeth works with Barretstown to help run
special camps for children with hemophilia.

Wyeth is also the founding and exclusive sponsor of NACCHO (North
American Camping Conference of Hemophilia Organizations). The annual
NACCHO conference is dedicated to the sharing of best practices for
bleeding disorder summer camps. Through NACCHO, children attending
summer camp also have the opportunity to participate in Leading Edge:
Exploring the Outer Limits, a nationally run adventure program that
focuses on self-confidence development for youth and adolescents in
the bleeding disorders community. Through its grants to NACCHO, Wyeth
has supported 1,000 campers nationally, and 500 campers
internationally.

Wyeth-Sponsored Support Programs

Education and access to care are critical to the health and
well-being of patients with hemophilia. In addition to other
initiatives that support the bleeding disorders community, Wyeth
proudly awards scholarships to deserving students who have
hemophilia. For the 2008-2009 academic year alone, Wyeth awarded up
to US$100,000 to students with bleeding disorders seeking collegiate,
graduate and vocational degrees. Wyeth also works to help patients
with hemophilia maintain access to hemophilia therapy. Through its
Factor Resource Program, Wyeth provides services designed to assist
patients experiencing financial hardship or treatment access issues,
including the Insurance-Coverage Program and the Patient Assistance
Program. Individuals can get more information about these programs
through the Wyeth Hemophilia Hotline (+1-888-999-2349).

Assisting Advocacy Organizations

Wyeth also provides assistance to numerous advocacy organizations
and their initiatives, including:

- WFH's Global Alliance for Progress (GAP) program, a 10-year healthcare
development initiative to facilitate earlier and accurate diagnosis and
treatment of people with hemophilia and other bleeding disorders in
developing countries.
- National Hemophilia Foundation's Campaign for Our Future, a program
designed to provide access to care for all members of the bleeding
disorders community.
- Hemophilia Federation of America's Helping Hands program, which
provides emergency financial assistance for members of the bleeding
disorders community. Last year, Wyeth supported 122 families through
its grants to the Hemophilia Federation of America.
- Coalition for Hemophilia B, an organization that provides information
about treatment that will improve the quality of life of patients with
hemophilia B.
- International Society for Thrombosis and Haemostasis, which fosters and
advances science relating to the important medical problems of
thrombosis and abnormalities of haemostasis and vascular biology.

Wyeth and Hemophilia

Wyeth works to help improve the health of hemophilia patients
through education, patient assistance programs and by supporting
associations throughout the world. For more information on Wyeth and
hemophilia, visit www.hemophiliavillage.com, a comprehensive site
that serves as a resource for patients, parents, and caregivers in
the hemophilia community.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products
in the areas of women's health care, infectious disease,
gastrointestinal health, central nervous system, inflammation,
transplantation, hemophilia, oncology, vaccines and nutritional
products.

Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies. It is a leader in
the discovery, development, manufacturing and marketing of
pharmaceuticals, vaccines, biotechnology products, nutritionals and
non-prescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal
Health.

The statements in this press release that are not historical
facts are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include, among others, risks related to our proposed
merger with Pfizer, including satisfaction of the conditions of the
proposed merger on the proposed timeframe or at all, contractual
restrictions on the conduct of our business included in the merger
agreement, and the potential for loss of key personnel, disruption in
key business activities or any impact on our relationships with third
parties as a result of the announcement of the proposed merger; the
inherent uncertainty of the timing and success of, and expense
associated with, research, development, regulatory approval and
commercialization of our products and pipeline products; government
cost-containment initiatives; restrictions on third-party payments
for our products; substantial competition in our industry, including
from branded and generic products; emerging data on our products and
pipeline products; the importance of strong performance from our
principal products and our anticipated new product introductions; the
highly regulated nature of our business; product liability,
intellectual property and other litigation risks and environmental
liabilities; the outcome of government investigations; uncertainty
regarding our intellectual property rights and those of others;
difficulties associated with, and regulatory compliance with respect
to, manufacturing of our products; risks associated with our
strategic relationships; global economic conditions; interest and
currency exchange rate fluctuations and volatility in the credit and
financial markets; changes in generally accepted accounting
principles; trade buying patterns; the impact of legislation and
regulatory compliance; risks and uncertainties associated with global
operations and sales; and other risks and uncertainties, including
those detailed from time to time in our periodic reports filed with
the Securities and Exchange Commission, including our current reports
on Form 8-K, quarterly reports on Form 10-Q and annual report on Form
10-K, particularly the discussion under the caption "Item 1A, Risk
Factors" in our Annual Report on Form 10-K for the year ended
December 31, 2008, which was filed with the Securities and Exchange
Commission on February 27, 2009. The forward-looking statements in
this press release are qualified by these risk factors. We assume no
obligation to publicly update any forward-looking statements, whether
as a result of new information, future developments or otherwise.

ots Originaltext: Wyeth Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media, Danielle Halstrom, Wyeth Pharmaceuticals, +1-484-865-2020, or
Douglas Petkus, Wyeth, +1-973-660-5218, or Investors, Justin
Victoria, Wyeth, +1-973-660-5340